Parkinson's Disease and Cognitive Impairment.

Yang Y, Tang BS, Guo JF
Parkinsons Dis. 2016;2016:6734678

Parkinson's disease (PD) is a progressive neurodegenerative disease primarily characterized by the hallmarks of motor symptoms, such as tremor, bradykinesia, rigidity, and postural instability. However, through clinical investigations in patients and experimental findings in animal models of Parkinson's disease for years, it is now well recognized that Parkinson's disease is more than just a motor-deficit disorder. The majority of Parkinson's disease patients suffer from nonmotor disabilities, for instance, cognitive impairment, autonomic dysfunction, sensory dysfunction, and sleep disorder. So far, anti-PD prescriptions and surgical treatments have been mainly focusing on motor dysfunctions, leaving cognitive impairment a marginal clinical field. Within the nonmotor symptoms, cognitive impairment is one of the most common and significant aspects of Parkinson's disease, and cognitive deficits such as dysexecutive syndrome and visuospatial disturbances could seriously affect the quality of life, reduce life expectancy, prolong the duration of hospitalization, and therefore increase burdens of caregiver and medical costs. In this review, we have done a retrospective study of the recent related researches on epidemiology, clinical manifestation and diagnosis, genetics, and potential treatment of cognitive deficits in Parkinson's disease, aiming to provide a summary of cognitive impairment in Parkinson's disease and make it easy for clinicians to tackle this challenging issue in their future practice.

Increased blood-brain barrier permeability is associated with dementia and diabetes but not amyloid pathology or APOE genotype.

Janelidze S, Hertze J, Nägga K, Nilsson K, Nilsson C, Swedish BioFINDER Study Group, Wennström M, van Westen D, Blennow K, Zetterberg H, Hansson O



Neurobiol Aging. 2016 Dec 05;51:104-112


Blood-brain barrier (BBB) dysfunction might be an important component of many neurodegenerative disorders. In this study, we investigated its role in dementia using large clinical cohorts. The cerebrospinal fluid (CSF)/plasma albumin ratio (Qalb), an indicator of BBB (and blood-CSF barrier) permeability, was measured in a total of 1015 individuals. The ratio was increased in patients with Alzheimer's disease, dementia with Lewy bodies or Parkinson's disease dementia, subcortical vascular dementia, and frontotemporal dementia compared with controls. However, this measure was not changed during preclinical or prodromal Alzheimer's disease and was not associated with amyloid positron emission tomography or APOE genotype. The Qalb was increased in diabetes mellitus and correlated positively with CSF biomarkers of angiogenesis and endothelial dysfunction (vascular endothelial growth factor, intracellular adhesion molecule 1, and vascular cell adhesion molecule 1). In healthy elderly, high body mass index and waist-hip ratio predicted increased Qalb 20 years later. In summary, BBB permeability is increased in major dementia disorders but does not relate to amyloid pathology or APOE genotype. Instead, BBB impairment may be associated with diabetes and brain microvascular damage.

Diagnostic Criteria and Classification of Alcohol-Related Dementia

Dementia
Dementia is defined as a significant deterioration of cognitive function sufficient to interfere in social or occupational functioning.
As defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, this requires a deterioration in memory and at least one other area of intellectual functioning. Moreover, the cognitive changes are not attributable to the presence of delirium or substance-induced intoxication or withdrawal.

Definite Alcohol-Related Dementia
At the current time, there are no acceptable criteria to define definitively alcohol-related dementia.
 
Probable Alcohol-Related Dementia
I. The criteria for the clinical diagnosis of probable alcohol-related dementia include the following:
a. A clinical diagnosis of dementia at least 60 days after the last exposure to alcohol.
b. Significant alcohol use as defined by a minimum average of 35 standard drinks per week for men and 28 for women for a period greater than 5 years. The period of significant alcohol use must occur within 3 years of the initial onset of dementia.
II. The diagnosis of alcohol-related dementia is supported by the presence of any of the following:
a. Alcohol-related hepatic, pancreatic, gastrointestinal, cardiovascular, or renal disease, i.e., other end-organ damage.
b. Ataxia or peripheral sensory polyneuropathy (not attributable to other specific causes).
c. Beyond 60 days of abstinence, the cognitive impairment stabilizes or improves.
d. After 60 days of abstinence, any neuroimaging evidence of ventricular or sulcal dilatation improves.
e. Neuroimaging evidence of cerebellar atrophy, especially of the vermis.
III. The following clinical features cast doubt on the diagnosis of alcohol-related dementia:
a. The presence of language impairment, especially dysnomia or anomia.
b. The presence of focal neurological signs or symptoms (except ataxia or peripheral sensory polyneuropathy).
c. Neuroimaging evidence for cortical or subcortical infarction, subdural hematoma, or other focal brain pathology.
d. Elevated Hachinski Ischemia Scale score.
IV. Clinical features that are neither supportive nor cast doubt on the diagnosis of alcohol-related dementia include the following:
a. Neuroimaging evidence of cortical atrophy.
b. The presence of periventricular or deep white matter lesions on neuroimaging in the absence of focal infarct(s).
c. The presence of the ApolipoproteinE ε4 allele.
V. The diagnosis of possible alcohol-related dementia may be made when there are
a. A clinical diagnosis of dementia at least 60 days after the last exposure to alcohol; and
b. Either:
1. Significant alcohol use, as defined by a minimum average of 35 standard drinks per week for men and 28 for women for 5 or more years; however, the period of significant alcohol use occurred more than 3 years but less than 10 years before the initial onset of cognitive deficits; or
2. Possibly significant alcohol use, as defined by a minimum average of 21 standard drinks per week for men and 14 for women but no more than 34 drinks per week for men and 27 for women for 5 years. The period of significant alcohol use must have occurred within 3 years of the onset of cognitive deficits.

Radiology Case of the Month: Acute Onset of Dizziness and Paresthesias in an Elderly Woman.

Shaikh MJ, Gupta JD

J La State Med Soc. 2016 Nov-Dec;168(6):218-220


61-year-old woman with a past medical history of dementia and Meniere's disease presents with acutely worsening dizziness and headache. The patient additionally complains of left greater than right upper extremity weakness and paresthesias.

NINDS-AIREN Criteria for the Diagnosis of Vascular Dementia

I. The criteria for the clinical diagnosis of probable vascular dementia include all of the following:
A. Dementia, defined by cognitive decline from a previously higher level of functioning and manifested by impairment of memory and of two or more cognitive domains (orientation, attention, language, visuospatial functions, executive functions, motor control, and praxis), preferably established by clinical examination and documented by neuropsychological testing; deficits should be severe enough to interfere with activities of daily living not because of physical effects of stroke alone.
Exclusion criteria: cases with disturbance of consciousness, delirium, psychosis, severe aphasia, or major sensorimotor impairment precluding neuropsychological testing. Also excluded are systemic disorders or other brain diseases (such as Alzheimer’s disease [AD]) that in and of themselves could account for deficits in memory and cognition.
B. Cerebrovascular disease, defined by the presence of focal signs on neurological examination, such as hemiparesis, lower facial weakness, Babinski sign, sensory deficit, hemianopia, and dysarthria consistent with stroke (with or without history of stroke), and evidence of relevant cerebrovascular disease (CVD) by brain imaging (computed tomography or magnetic resonance imaging [MRI]) including multiple large-vessel infarcts or a single strategically placed infarct (angular gyrus, thalamus, basal forebrain, or posterior cerebral artery or anterior cerebral artery territories), as well as multiple basal ganglia and white matter lacunes, or extensive periventricular white matter lesions, or combinations thereof.
C. A relationship between the above two disorders, manifested or inferred by the presence of one or more of the following:
a. Onset of dementia within 3 months following a recognized stroke.
b. Abrupt deterioration in cognitive functions.
c. Fluctuating, stepwise progression of cognitive deficits.
II. Clinical features consistent with the diagnosis of probable vascular dementia include the following:
A. Early presence of gait disturbance (small-step gait or marche a petits pas, or magnetic, apraxic-ataxic or parkinsonian gait).
B. History of unsteadiness and frequent, unprovoked falls.
C. Early urinary frequency, urgency, and other urinary symptoms not explained by urological disease.
D. Pseudobulbar palsy.
E. Personality and mood changes, abulia, depression, emotional incontinence, or other subcortical deficits including psychomotor retardation and abnormal executive function.
III. Features that make the diagnosis of vascular dementia uncertain or unlikely include the following:
A. Early onset of memory deficit and progressive worsening of memory deficit and progressive worsening of memory and other cognitive functions, such as language (transcortical sensory aphasia), motor skills (apraxia), and perception (agnosia), in the absence of corresponding focal lesions on brain imaging.
B. Absence of focal neurological signs, other than cognitive disturbance.
C. Absence of cerebrovascular lesions on brain CT or MRI.
IV. Clinical diagnosis of possible vascular dementia may be made in the presence of dementia (section I-A) with focal neurological signs in patients in whom brain imaging studies to confirm definite CVD are missing; or in the absence of clear temporal relationship between dementia and stroke; or in patients with subtle onset and variable course (plateau or improvement) of cognitive deficits and evidence of relevant CVD.
V. Criteria for diagnosis of definite vascular dementia are:
A. Clinical criteria for probable vascular dementia.
B. Histopathological evidence of CVD obtained from biopsy or autopsy.
C. Absence of neurofibrillary tangles and neuritic plaques exceeding those expected for age.
D. Absence of other clinical or pathological disorder capable of producing dementia.
VI. Classification of vascular dementia for research purposes may be made based on clinical, radiological, and neuropathological features, for subcategories or defined conditions, such as cortical vascular dementia, subcortical vascular dementia, Binswanger’s disease, and thalamic dementia.

Dementia and Pressure Ulcers: Is There a Close Pathophysiological Interrelation

Jaul E, Meiron O
J Alzheimers Dis. 2016 Dec 30;:

        The current theoretical investigation aimed to explore common pathophysiological mechanisms underlying dementia and pressure ulcers (PU). Along with the increased longevity, especially in frail elderly patients, there is a higher rate of functional and cognitive impairment with dementia coinciding with disabilities, immobility resulting in a higher rate of PU. Understanding common etiological paths resulting in pressure ulcers and dementia is likely to produce new treatment strategies that could lead to the prevention of comorbid complications. Data collected from elderly dementia patients indicate a deterioration of several neurophysiological subsystems associated with motor, sensory, autonomic, cognitive, or behavioral pathways, supporting a "close pathophysiological interrelation" perspective linking PU with dementia progression. Overall, the authors' theoretical systemic-model of disease progression and PU comorbidity proposes that increased clinician awareness to PU in mild to moderate dementia may suppress the accelerated development of PU, resulting in less patient suffering, reduced long-term care hospitalization, and hopefully PU prevention.

Spatio-temporal and kinematic gait analysis in patients with Frontotemporal dementia and Alzheimer's disease through 3D motion capture.

Rucco R, Agosti V, Jacini F, Sorrentino P, Varriale P, De Stefano M, Milan G, Montella P, Sorrentino G
Gait Posture. 2016 Dec 21;52:312-317

        Alzheimer's disease (AD) and behavioral variant of Frontotemporal Dementia (bvFTD) are characterized respectively by atrophy in the medial temporal lobe with memory loss and prefrontal and anterior temporal degeneration with dysexecutive syndrome. In this study, we hypothesized that specific gait patterns are induced by either frontal or temporal degeneration. To test this hypothesis, we studied the gait pattern in bvFTD (23) and AD (22) patients in single and dual task ("motor" and "cognitive") conditions. To detect subtle alterations, we performed motion analysis estimating both spatio-temporal parameters and joint excursions. In the single task condition, the bvFTD group was more unstable and slower compared to healthy subjects, while only two stability parameters were compromised in the AD group. During the motor dual task, both velocity and stability parameters worsened further in the bvFTD group. In the same experimental conditions, AD patients showed a significantly lower speed and stride length than healthy subjects. During the cognitive dual task, a further impairment of velocity and stability parameters was observed in the bvFTD group. Interestingly, during the cognitive dual task, the gait performance of the AD group markedly deteriorated, as documented by the impairment of more indices of velocity and stability. Finally, the kinematic data of thigh, knee, and ankle were more helpful in revealing gait impairment than the spatio-temporal parameters alone. In conclusion, our data showed that the dysexecutive syndrome induces specific gait alterations. Furthermore, our results suggest that the gait worsens in the AD patients when the cognitive resources are stressed.

DSM-IV Criteria for the Diagnosis of Vascular Dementia

1. The development of multiple cognitive deficits manifested by both memory impairment (impaired ability to learn new information or to recall previously learned information) and one or more of the following cognitive disturbances: 
 a. Aphasia (language disturbance). 
 b. Apraxia (impaired ability to carry out motor activities despite intact motor function). 
 c. Agnosia (failure to recognize or identify objects despite intact sensory function). 
 d. Disturbance in executive functioning (i.e., planning, organizing, sequencing, abstracting). 
2. The cognitive deficits in criteria 1a and 1b each cause significant impairment in social or occupational functioning and represent a significant decline from a previous level of functioning. 
3. Focal neurological signs and symptoms (e.g., exaggeration of deep tendon reflexes, extensor plantar response, pseudobulbar palsy, gait abnormalities, weakness of an extremity), or laboratory evidence indicative of cerebrovascular disease (e.g., multiple infarctions involving cortex and underlying white matter) that are judged to be etiologically related to the disturbance. 
4. The deficits do not occur exclusively during the course of a delirium. 

American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th rev. ed. Washington, DC: American Psychiatric Association, 1994.

Diagnostic decision tree in dementia


Julie Loebach Wetherell
Dialogues Clin Neurosci. 2003 Mar; 5(1): 44–47.
 
Diagnostic criteria for dementia include memory impairment plus impairment in at least one other cognitive function, including aphasia, apraxia, agnosia, or disturbance in executive functioning. These deficits must represent a decline from a previous level of functioning and be sufficiently severe to cause significant impairment in social or occupational performance. The diagnosis of dementia begins with a patient, presenting with memory difficulties or other complaints. These can include apathy or lack of initiative, disorientation, sleep-wake cycle disturbance, aggression, disinhibition, agitation, depression, anxiety, or psychotic symptoms, as well as impairment in cognitive domains such as attention and concentration, language, motor coordination, recognition of objects, visuospatial skills, insight, and judgment.

DSM-IV-TR Diagnostic criteria for Alzheimer's Disease (AD)


A. The development of multiple cognitive deficits manifested by both memory impairment and one or more of the following
  1. Aphasia
  2. Apraxia
  3. Agnosia
  4. and disturbances in executive functioning
B. The cognitive deficits represent as decline from previous functioning and cause significant impairment in social or occupational functioning

C. The course is characterized by gradual onset and continuing decline

D. The cognitive deficits are not due to other central nervous system, systemic, or substance-induced conditions that cause progressive deficits in memory and cognition

E. The disturbance is not better accounted for by another psychiatric disorder.

NINDS-ADRDA Diagnostic criteria for Alzheimer's Disease (AD)

Probable AD: A plus one or more supportive features B, C, D, or E
Core diagnostic criteria
A. Presence of an early and significant episodic memory impairment that includes the following features:
  1. Gradual and progressive change in memory function reported by patients or informants over more than 6 months
  2. Objective evidence of significantly impaired episodic memory on testing: this generally consists of recall deficit that does not improve significantly or does not normalise with cueing or recognition testing and after effective encoding of information has been previously controlled
  3. The episodic memory impairment can be isolated or associated with other cognitive changes at the onset of AD or as AD advances
Supportive features
B. Presence of medial temporal lobe atrophy
  1. Volume loss of hippocampi, entorhinal cortex, amygdala evidenced on MRI with qualitative ratings using visual scoring (referenced to well characterised population with age norms) or quantitative volumetry of regions of interest (referenced to well characterised population with age norms)
C. Abnormal cerebrospinal fluid biomarker
  1. Low amyloid ?1–42 concentrations, increased total tau concentrations, or increased phospho-tau concentrations, or combinations of the three
  2. Other well validated markers to be discovered in the future
D. Specific pattern on functional neuroimaging with PET
  1. Reduced glucose metabolism in bilateral temporal parietal regions
  2. Other well validated ligands, including those that foreseeably will emerge such as Pittsburg compound B or FDDNP
E. Proven AD autosomal dominant mutation within the immediate family
 
Exclusion criteria
  1. History
  2. Sudden onset
  3. Early occurrence of the following symptoms: gait disturbances, seizures, behavioural changes
  4. Clinical features
  5. Focal neurological features including hemiparesis, sensory loss, visual field deficits
  6. Early extrapyramidal signs
  7. Other medical disorders severe enough to account for memory and related symptoms
Non-AD dementia, Major depression, Cerebrovascular disease, Toxic and metabolic abnormalities, all of which may require specific investigations
MRI FLAIR or T2 signal abnormalities in the medial temporal lobe that are consistent with infectious or vascular insults
Criteria for definite AD
AD is considered definite if the following are present:
  1. Both clinical and histopathological (brain biopsy or autopsy) evidence of the disease, as required by the NIA-Reagan criteria for the post-mortem diagnosis of AD; criteria must both be present
  2. Both clinical and genetic evidence (mutation on chromosome 1, 14, or 21) of AD; criteria must both be present

Association of Cancer History with Alzheimer's Disease Dementia and Neuropathology.

Yarchoan M, James BD, Shah RC, Arvanitakis Z, Wilson RS, Schneider J, Bennett DA, Arnold SE ; J Alzheimers Dis. 2016 Dec 30;:


BACKGROUND: Cancer and Alzheimer's disease (AD) are common diseases of aging and share many risk factors. Surprisingly, however, epidemiologic data from several recent independent cohort studies suggest that there may be an inverse association between these diseases.
OBJECTIVE: To determine the relationship between history of cancer and odds of dementia proximate to death and neuropathological indices of AD.
METHODS: Using data from two separate clinical-pathologic cohort studies of aging and AD, the Religious Orders Study (ROS) and the Rush Memory and Aging Project (MAP), we compared odds of AD dementia proximate to death among participants with and without a history of cancer. We then examined the relation of history of cancer with measures of AD pathology at autopsy, i.e., paired helical filament tau (PHFtau) neurofibrillary tangles and amyloid-β load.
RESULTS: Participants reporting a history of cancer had significantly lower odds of AD (OR 0.70 [0.55-0.89], p=0.0040) proximate to death as compared to participants reporting no prior history of cancer. The results remained significant after adjusting for multiple risk factors including age, sex, race, education, and presence of an APOEɛ4 allele. At autopsy, participants with a history of cancer had significantly fewer PHFtau tangles (p<0.001) than participants without a history of cancer, but similar levels of amyloid-β.
CONCLUSIONS: Cancer survivors have reduced odds of developing AD and a lower burden of neurofibrillary tangle deposition.